
The Breakthrough Properties co-founder has made a career out of an overlooked biotech constraint: before researchers can change the world, somebody has to build a laboratory that actually works.
A $3 billion fund, six million square feet and one useful insight: scientists should not have to teach their landlord how a lab works. Now a sector-wide glut is testing whether Breakthrough's hospitality-heavy, biotech-native model can earn its keep.

After a career scaling antibody production and biomanufacturing systems, the SmartLabs CEO is betting that the next research breakthrough may depend on something less glamorous: a laboratory that can change as quickly as the science.
Tamarind Bio is a San Francisco software company building cloud infrastructure that lets bench scientists run 250+ AI and physics-based models for drug discovery - tools like AlphaFold, RFdiffusion, ProteinMPNN and GROMACS - through a no-code web interface and API, without managing GPUs, data pipelines or DevOps. Founded in 2023 by Stanford computer scientist Deniz Kavi and Sherry Liu, the company serves over 10,000 scientists, including 8 of the top 20 pharmaceutical companies, and raised a $13.6M Series A in February 2026.